← All trials
NCT05278546
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2022
- Primary completion
- Nov 30, 2023
- Completion date
- Jan 31, 2024
- First posted
- Mar 14, 2022
- Last posted
- Mar 29, 2022
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Innolake BiopharmLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Shandong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.